

Neuro Task Force Next Steps


Rosa Canet-Avilés, PhD
VP Scientific Programs & Education

Neuro Task Force
April 17, 2024



1. NTF Next Steps

ReMIND Concept



Total Research Budget

From Prop 71 & Prop 14

\$7.64B



Current Research Allocation

Excluding expended/scheduled payments & approved allocations

Remaining Balance: **\$3.54B**

- For Neuro Research: **\$1.11B**
- Access & Affordability: **\$93.56M**

➤ W/o specific action - Current rate of expenditure is **33%** (> 27%)

NTF will inform specific aspects of the **Recommendations**



**Impact Goals /
SAF Categories**



**Guiding
Questions**



**Data Collection &
Analysis**



**CIRM
Recommendation**



1. Approval of Cell and Gene Therapies
2. Accessibility and Affordability of CIRM-Funded Cell and Gene Therapies
3. Discovery of Novel Disease Mechanisms
4. Diverse Workforce Development

Determine:

- How can CIRM make the greatest impact on its mission in the **Neuro** space?
- How might CIRM effectively allocate its remaining **Neuro budget of \$1.11B**?



- 1. Focused Neuro Investment:** Should any areas of Neuro be singled out for enhanced funding?
- 2. Portfolio Reassessment:** What criteria should guide any revisions to our current funding portfolio, and what adjustments might be needed?
- 3. Strategic Direction in Research Phases:** How should we delineate our focus between translational/clinical and discovery stages within neuro research?
- 4. Special Project Funding Allocation:** What proportion of our Neuro budget should be earmarked for task force-identified projects?
 - **Should any of the Neuro set-aside be used for phase 1 clinical trials of small molecules?**
- 5. Neuro Task Force Scope:** Beyond the fields of neurodegeneration, and neuro injury (stroke, TBI), are there other areas that the Neuro task force should consider before finalizing our plan?
- 6. Process:** What degree of specificity should we include in our proposed plan to the science, subcommittee and the ICOC?



1. Focused Neuro Investment:

- a. Prevalence and burden of neurological conditions in CA
- b. Landscape analysis of current research funding and gaps in the neuro field
- c. Expert consensus on emerging areas within neurosciences with high potential for breakthroughs

2. Portfolio Reassessment:

- a. Historical performance data of funded projects (e.g., publication rates, subsequent funding, clinical impact)
- b. Comparative analysis of funding portfolios and strategies with peer organizations
- c. Data on industry trends and alignment with strategic health priorities

3. Strategic Direction in Research Phases:

- a. Success rates and timelines of translational/clinical projects (modalities, diseases)
- b. Analysis of bottlenecks and challenges at different stages of neuro research (see 1)
- c. Potential for translation of research findings into clinical practice or commercialization within CIRM's lifetime



4. Special Project Funding Allocation

a. Small molecule repurposing

- i. Data on the costs, outcomes, and return on investment of Phase 1 clinical trials for repurposed small molecules in neurosciences
- ii. Comparative costs of phase 1 trials for repurposed small molecules versus new drug entities.
- iii. Information on any expedited pathways available for repurposed drugs that may shorten the time to trial completion and reduce costs.

5. NTF Scope:

- a. Landscape analysis of current research in neurosciences beyond neurodegeneration and neuro injury
- b. Identification of underfunded areas/phases with high potential impact
- c. Consensus statements or position papers from leading neuroscience research bodies

6. Process:

- a. Refer to SAF process

ReMIND Concept

